← boardnext 2026-08
MANE
Veradermics, Inc.distress 2/10 · well-funded / low risk$111.25+1%today-14% from 52w high
Dermatology 2
Lead: Androgenetic Alopecia
Revenue
pre-revenue
Liquidity
$168M
Runway
2.4 yrs
Shares 1y
+12%
Price & events
+194.7% over 6M
CatalystRating changeDilutionFinancingdashed = today
+1.3%
1D
+5.1%
1W
+7.4%
1M
+60.6%
3M
—
6M
—
1Y
—
2Y
—
5Y
+194.7%
All
Overview
- Market Cap
- $4.65B
- Volume
- 31.67K
- 52 Week Range
- $37.03 – $130
- Total Shares
- 41.78M
- Float Shares
- 27.21M
- Short %
- 14.00%
- % Held by Insiders
- 2.74%
- % Held by Institutions
- 80.00%
- RVOL
- 0.04x
Pipeline stages · 2 programs
VDPHL01 QD, VDPHL01 BID
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
VDMN-21 Patch Low Dose, VDMN-21 Patch High Dose, Vehicle Patch
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 5 trials · 3 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-08 Estimated 50% readout ~2026-09-15 final ~2027-02-28 | Phase 2 | VDPHL01 | Androgenetic Alopecia, AGA, Male Pattern Baldness | 70 | active not recruiting |
| 2026-12 Estimated 50% readout ~2027-02-14 | Phase 3 | VDPHL01 | Androgenetic Alopecia, AGA, Male Pattern Baldness | — | active not recruiting |
| 2027-06 Estimated 50% readout ~2027-08-15 | Phase 3 | VDPHL01 QD, VDPHL01 BID | Androgenetic Alopecia (AGA), Androgenetic Alopecia, AGA, Female Androgenetic Alopecia, Hair Loss | — | recruiting |
| 2026-02 | Phase 2/3 | VDPHL01 | Androgenetic Alopecia, AGA, Male Pattern Baldness | 480 | active not recruiting |
| 2025-02-25 | Phase 2 | VDMN-21 Patch Low Dose, VDMN-21 Patch High Dose, Vehicle Patch | Verruca Vulgaris, Warts, Common Wart | 153 | completed |
Catalyst news & presentations · 2
- 2026-08-13Estimated 45%earningsEarningsEarnings releaseyahoo
- April 27, 2026readoutPhase 2/3VDPHL01 · Positive topline data from Study '302' evaluating VDPHL01 in males with mild-to-moderate pattern hair loss.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $161 (+45% upside) · 6 analysts
- 2026-07-16CitigroupBuy
- 2026-07-15NeedhamBuy
- 2026-07-15B. Riley SecuritiesBuy
- 2026-07-07JefferiesBuy
- 2026-06-16LifeSci CapitalOutperform
- 2026-06-02NeedhamBuy
Competitors — Androgenetic Alopecia
- ABSIAbsci Corp$1.2B · D5
Recent news
- 2026-07-21MANE Price Today: Veradermics, Incorporated Stock Price, Quote & Chart | MEXC - MEXC
- 2026-07-17PayPal, Veradermics, Alibaba and other big stocks moving higher on Wednesday - MSN
- 2026-07-17Veradermics Announces Presentations of Data from a Subgroup Analysis of Phase 2/3 Study ‘302’ in Males with Pattern Hair Loss at 2026 American Academy of Dermatology Innovation Academy - Business Wire
- 2026-07-17Veradermics Announces Presentations of Data from a Subgroup Analysis of Phase 2/3 Study ‘302’ in Males with Pattern Hair Loss at 2026 American Academy of Dermatology Innovation Academy - Yahoo Finance
- 2026-07-17Veradermics Announces Presentations of Data from a Subgroup Analysis of Phase 2/3 Study ‘302’ in Males with Pattern Hair Loss at 2026 American Academy of Dermatology Innovation Academy - Business Wire
- 2026-07-16MANE Maintained by Citigroup -- Price Target Raised to $160 - GuruFocus
- 2026-07-16PayPal, Veradermics, Alibaba and other big stocks moving higher on Wednesday - MSN
- 2026-07-15Veradermics' Oral Hair Loss Drug for Women Shows Results In Just 2 Months - Benzinga
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.